Zoetis Inc. $ZTS Position Increased by BHK Investment Advisors LLC

BHK Investment Advisors LLC grew its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 21.6% during the second quarter, Holdings Channel reports. The firm owned 4,197 shares of the company’s stock after acquiring an additional 745 shares during the quarter. BHK Investment Advisors LLC’s holdings in Zoetis were worth $655,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of ZTS. Nova Wealth Management Inc. acquired a new stake in Zoetis during the first quarter worth about $25,000. 1248 Management LLC acquired a new position in Zoetis in the first quarter valued at approximately $27,000. Saudi Central Bank bought a new position in shares of Zoetis during the first quarter valued at approximately $29,000. REAP Financial Group LLC raised its position in shares of Zoetis by 201.5% during the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after purchasing an additional 131 shares during the period. Finally, Cornerstone Planning Group LLC lifted its holdings in shares of Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after purchasing an additional 88 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Price Performance

Shares of NYSE ZTS opened at $120.20 on Friday. The stock has a market cap of $53.27 billion, a P/E ratio of 20.69, a P/E/G ratio of 2.31 and a beta of 0.90. The firm’s 50-day simple moving average is $144.21 and its 200 day simple moving average is $152.60. Zoetis Inc. has a fifty-two week low of $117.26 and a fifty-two week high of $181.85. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.62 by $0.08. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.42 billion. During the same quarter last year, the company earned $1.58 EPS. Zoetis’s quarterly revenue was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 annualized dividend and a yield of 1.7%. Zoetis’s payout ratio is presently 33.67%.

Wall Street Analyst Weigh In

ZTS has been the subject of a number of recent research reports. Argus restated a “buy” rating and set a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Piper Sandler boosted their price target on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Stifel Nicolaus set a $140.00 price objective on shares of Zoetis in a research report on Tuesday. Finally, Leerink Partners cut shares of Zoetis from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Five investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Zoetis has an average rating of “Moderate Buy” and a consensus target price of $191.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.